Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

摘要: Drugs that target the vascular endothelial growth factor (VEGF) and platelet derived (PDGF) pathways have revolutionized treatment of patients with metastatic renal cell cancer (RCC). Patients clear RCC often mutations or silencing von Hippel Lindau gene leading to an accumulation HIF 1 alpha. This allows factors such as VEGF PDGF be upregulated promote angiogenesis stabilization. Both sunitinib sorafenib receptor tyrosine kinases while bevacizumab is a monoclonal antibody VEGF. These three agents demonstrated superior progression free survival in when compared interferon placebo. Newer anti-VEGF axitinib, pazopanib cediranib are currently under investigation elucidate future options. The mammalian rapamycin (mTOR) downstream pathway has been targeted drugs including temsirolimus everolimus. review will detail pharmacologic molecular activity these how they translate into clinical efficacy.